Valencia

• A trial to learn how safe AZD0022 is, how well it works, and how it moves throughout the body over time in adults with tumors that have a KR … Ended
  2024-516699-14-00 7 2025-04-23 Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenoca
• Phase 1 trial of LAVA-1266, a CD123-targeting bispecific Vγ9Vδ2-T cell engager, in patients with CD123 positive relapsed/refractory (R/R) ac … Ended
  2024-518831-12-00 1 2025-04-15 CD123 positive R/R AML and intermediate risk, high risk, or extremely
• A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th … Ended
  2024-515539-31-00 4 2025-04-01 Alzheimer’s disease dementia
• Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® … Ended
  2023-507865-24-00 5 2025-03-28 Advanced (unresectable/metastatic) melanoma
• A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together with Either Pembrolizumab, Standard Therapies, or Both, in Adults with Solid T … Ended
  2023-505084-37-00 7 2025-03-17 Advanced Solid Tumors
• AKTive-001: A Phase 1/1b Multiple Cohort Trial of ALTA2618 in Patients with Advanced Solid Tumors with AKT1 E17K Mutation Ended
  2024-515391-12-00 1 2025-03-15 Advanced Solid Tumors with AKT1 E17K Mutation
• Phase 1/2 Study of Cobolimab plus Dostarlimab in Pediatric and Young Adult Participants with Newly Diagnosed and Relapsed/Refractory Tumors Ended
  2024-511350-41-00 9 2025-03-13 Relapsed/Refractory Tumors
• A Study of ZL-1218 with or without Pembrolizumab in Subjects with Advanced Solid Tumor Cancers to Find a Suitable Dose and to Test How Diffe … Ended
  2022-503102-20-00 1 2025-03-10 Advanced solid tumors
• Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated Ended
  2024-512505-66-00 10 2025-03-03 HIV-1 Infection
• Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac … Ended
  2023-508959-39-00 5 2025-02-20 Moderate to Severe Plaque Psoriasis
• N/A Ended
  2024-513121-22-00 4 2025-02-04 Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
• Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated … Ended
  2024-511030-12-00 3 2025-02-03 Non-small Cell Lung Cancer (NSCLC)
• A trial to learn how well NMS-01940153E works in combination with atezolizumab and priming administration of decitabine or with atezolizumab … Ended
  2024-516737-12-00 4 2025-01-28 Unresectable Hepatocellular Carcinoma (HCC)
• Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A Ended
  2023-505801-17-00 2 2025-01-15 Haemophilia A
• A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1) Ended
  2024-514559-13-00 10 2024-11-26 Focal Epilepsy
• A Phase 1/2 Study of VX-522 in Subjects with Cystic Fibrosis Ended
  2023-504786-23-00 7 2024-11-18 Cystic Fibrosis
• A multicentre clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax … Ended
  2024-519275-26-00 9 2024-11-15 Newly diagnosed acute myeloid leukemia patients aged equal or more tha
• A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended
  2023-507563-19-00 5 2024-11-05 Thyroid eye disease
• Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat … Ended
  2023-508474-29-00 4 2024-10-30 Dermatitis, Atopic
• An open label, multicenter, phase II study of belantamab mafodotin in combination with VRd for the treatment of newly diagnosed transplant e … Ended
  2024-516130-35-00 4 2024-09-26 Multiple myeloma
• A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended
  2024-511363-28-00 5 2024-09-24 hidradenitis suppurativa (HS)
• Safety and Efficacy of NMD670 in Adult Patients with Type 1 and Type 2 Charcot-Marie-Tooth Disease Ended
  2023-507892-23-00 4 2024-08-30 Charcot-Marie-Tooth Disease Type 1 and Type 2
• First-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retrope … Ended
  2024-516971-34-00 1 2024-08-20 Recurrent or locally advanced retroperitoneal soft tissue sarcoma
• Phase 2 Study of BB-1701 in HER2 positive or HER2-low metastatic breast cancer Ended
  2023-506866-30-00 4 2024-08-19 HER2 positive or HER2-low metastatic breast cancer

Showing 1,441–1,464 of 1,853 trials